Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals AB's revenue for the
three
months ended in Feb. 2026 was €0.80 Mil.
Its revenue for the trailing twelve months (TTM) ended in Feb. 2026 was €3.01 Mil.
Newbury Pharmaceuticals AB's Revenue per Share for the
three
months ended in Feb. 2026 was €0.03.
Its Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was €0.10.
Warning Sign:
Newbury Pharmaceuticals AB revenue per share is in decline over the past 12 months.
During the past 5 years, Newbury Pharmaceuticals AB's highest 3-Year average Revenue per Share Growth Rate was 103.50% per year. The lowest was 54.30% per year. And the median was 78.90% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Newbury Pharmaceuticals AB Revenue Related Terms
Newbury Pharmaceuticals AB Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Revenue distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (FRA:P52) has a Revenue of €3.01 Mil as of Feb. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Revenue too high?
Newbury Pharmaceuticals AB's current Revenue is €3.01 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Revenue compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Revenue of €3.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Revenue is €3.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Revenue of €3.01 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Revenue is €3.01 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Revenue is €3.01 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
Revenue: €3.01 Mil
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score
Get the complete analysis for FRA:P52
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
